Hypothesis: Intermittent HIF-1α Stabilization and mTORC1 Inhibition Amplify OSK-Mediated Rejuvenation While Suppressing Tumorigenic Escape

Core Idea Cyclic OSK expression resets epigenetic age, but transient pluripotency carries a risk of teratoma formation. We propose that pairing each OSK pulse with a short window of HIF-1α stabilization (e.g., using DMOG) and following the rest period with low-dose mTORC1 inhibition (e.g., rapamycin) will:

1. Enhance chromatin accessibility at senescence‑associated promoters, allowing OSK factors to engage target loci more efficiently.
2. Shift cellular metabolism toward oxidative phosphorylation during the HIF‑1α window, reducing the glycolytic bias that supports pluripotent expansion.
3. Limit proliferation of any OSK‑induced pluripotent‑like cells via mTORC1–driven growth arrest during the rest phase, giving pharmacological suicide mechanisms (e.g., YM155) a cleaner window to act.

Mechanistic Rationale HIF‑1α activation induces expression of chromatin remodelers such as KDM4A and p300, which increase H3K9ac and H3K27ac marks at loci silenced in aged cells. This creates a permissive landscape for OSK‑driven demethylation of pluripotency genes without sustaining a full pluripotent transcriptional program. Concurrently, HIF‑1α shifts metabolism from glycolysis to TCA cycle activity, lowering the production of oncometabolites (e.g., succinate) that can stabilize pluripotency.

During the subsequent rest phase, rapamycin‑mediated mTORC1 inhibition reduces protein synthesis and cell cycle progression, effectively quenching any residual pluripotent cell expansion. This creates a temporal window where survivin inhibitors or HSV‑TK suicide switches can eliminate stray cells before they form teratomas.

Testable Predictions

• In 124‑week‑old mice, OSK pulses (2 days on/5 days off) combined with daily DMOG during the ON days and rapamycin (0.5 mg/kg) during the OFF days will increase median remaining lifespan by >150 % relative to untreated controls, surpassing the 109 % gain reported for OSK alone 1.
• Teratoma incidence will remain <1 % across cohorts, matching or improving the zero‑tumor outcome seen with OSK plus YM155 pretreatment 2.
• Multi‑tissue epigenetic clocks will show a greater reduction in predicted biological age (≥0.8 years) compared with OSK‑only groups, reflecting enhanced resetting.
• RNA‑seq of liver and muscle will reveal up‑regulation of oxidative phosphorylation genes and down‑regulation of pluripotency network genes (e.g., Nanog, Sox2) only in the combined treatment arm.

Falsifiability If the combined regimen fails to extend lifespan beyond OSK alone, or if teratoma formation rises above baseline, the hypothesis is refuted. Likewise, absence of metabolic shift or epigenetic acceleration would invalidate the proposed mechanistic link.

Implementation Notes

• Use doxycycline‑inducible OSK AAV9 constructs for body‑wide delivery.
• Administer DMOG (50 mg/kg i.p.) only during OSK ON days.
• Deliver rapamycin via chow or i.p. injection during OFF days.
• Monitor plasma cytokine levels and perform weekly ultrasound to detect early teratoma signs.

By layering metabolic and growth‑control interventions onto existing safety protocols, this approach aims to push partial reprogramming closer to clinical feasibility without compromising its rejuvenative potency.